Skip to Content
Merck

Skip To

SML3117

N-Desethyl sunitinib hydrochloride

≥98% (HPLC)

Promotion Available

Synonym(s):

5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylaminoethyl)amide hydrochloride, N-Desethylsunitinib hydrochloride, N-[2-(Ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide hydrochloride, SU 12662 hydrochloride, SU12662 hydrochloride

Sign In to View Organizational & Contract Pricing.

Spend 10 750 CZK — Save 5%; Spend 15 250 CZK — Save 10%; Spend 28 000 CZK — Save 15%*

Sign in to check eligibility. Shop Products

Select a Size

Change View
Size/SKUAvailabilityPrice
5 mg
Please contact Customer Service for Availability
3 530,00 CZK
25 mg
Please contact Customer Service for Availability
11 700,00 CZK

About This Item

Empirical Formula (Hill Notation):
C20H23FN4O2 · xHCl
CAS Number:
Molecular Weight:
370.42 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated

3 530,00 CZK

Save Up To 15%


Please contact Customer Service for Availability

​
Request a Custom Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Quality Segment

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

Fc1cc2c(cc1)NC(=O)\C\2=C/c3[nH]c(c(c3C)C(=O)NCCNCC)C

InChI

1S/C20H23FN4O2/c1-4-22-7-8-23-20(27)18-11(2)17(24-12(18)3)10-15-14-9-13(21)5-6-16(14)25-19(15)26/h5-6,9-10,22,24H,4,7-8H2,1-3H3,(H,23,27)(H,25,26)/b15-10-

InChI key

LIZNIAKSBJKPQC-GDNBJRDFSA-N

Biochem/physiol Actions

Multi-target tyrosine kinase inhibitor (TKI); major and pharmacologically active metabolite of an anticancer drug sunitinib;
N-Desethyl sunitinib is a multi-target tyrosine kinase inhibitor that is a major active metabolite of an anticancer drug sunitinib. N-Desethyl sunitinib has a similar kinase inhibitory effect as sunitinib. In patients, plasma sunitinib and N-desethyl sunitinib accounts for 42% and 24%, respectively. Thus N-desethyl sunitinib accounts for one third of the therapeutic effect of oral sunitinib.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
SML1576SML3369SML3262
description

≥98% (HPLC)

description

≥95% (HPLC)

description

≥98% (HPLC)

description

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥95% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

−20°C

storage temp.

-10 to -25°C

storage temp.

2-8°C

solubility

DMSO: 2 mg/mL, clear (warmed)

solubility

-

solubility

H2O: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

storage condition

desiccated

storage condition

protect from light, desiccated

storage condition

desiccated

storage condition

desiccated


pictograms

Health hazardEnvironment

signalword

Warning

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 2 - STOT RE 2

target_organs

blood vessel,Bone marrow

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Questions

Reviews

No rating value

Active Filters